aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-752Research ArticleОБЗОРЫREVIEWSКлинические исследования моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9АстраковаК. С.AstrakovaK. S.

Ксения Сергеевна Астракова, аспирант

630089

ул. Бориса Богаткова, 175/1

Новосибирск

630089

Boris Bogatkov str., 175/1

Novosibirsk

astramedicina@mail.ruРагиноЮ. И.RaginoYu. I.

Юлия Игоревна Рагино, д-р мед. наук, проф., зав. лабораторией

лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

630089

Boris Bogatkov str., 175/1

Novosibirsk

ragino@mail.ruШахтшнейдерЕ. В.ShakhtshneiderE. V.

Елена Владимировна Шахтшнейдер, канд. мед. наук, ведущий научный сотрудник

лаборатория молекулярно-генетических исследований терапевтических заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

630089

Boris Bogatkov str., 175/1

Novosibirsk

2117409@mail.ruВоеводаМ. И.VoevodaM. I.

Михаил Иванович Воевода, д-р мед. наук, проф., член-корр., директор

630089

ул. Бориса Богаткова, 175/1

Новосибирск

630089

Boris Bogatkov str., 175/1

Novosibirsk

mvoevoda@ya.ruФГБНУ «НИИ терапии и профилактической медицины»Institute of Internal and Preventive Medicine2015170420221124349Copyright © Астракова К.С., Рагино Ю.И., Шахтшнейдер Е.В., Воевода М.И., 20222022Астракова К.С., Рагино Ю.И., Шахтшнейдер Е.В., Воевода М.И.Astrakova K.S., Ragino Y.I., Shakhtshneider E.V., Voevoda M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/752

   В обзоре представлены данные современной научной литературы о различных фазах клинических исследований моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9 (PCSK9). Приведены результаты законченных клинических исследований. Дан обзор клинических исследований, которые завершаются в 2015–2018 гг.

   The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of clinical studies that will be complete in the 2015–2018’s are presented.

пропротеиновая конвертаза субтилизин-кексинового типа 9PCSK9гиперхолестеринемиясемейная гиперхолестеринемиямоноклональные антителаproprotein convertase subtilisin / kexin type 9PCSK9hypercholesterolemiaFamilial HypercholesterolemiaMonoclonal antibodiesReferencesRidker P. M. LDL cholesterol: controversies and future therapeutic directions // Lancet. 2014. Vol. 384. P. 607–617.Ridker P. M. LDL cholesterol: controversies and future therapeutic directions // Lancet. 2014. Vol. 384. P. 607–617.Stein E. A., Mellis S., Yancopoulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366, N 12. P. 1108–1118.Stein E. A., Mellis S., Yancopoulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366, N 12. P. 1108–1118.Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo- controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Vol. 60, N 19. P. 1888–1898.Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo- controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Vol. 60, N 19. P. 1888–1898.Clinical Trials gov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). – http://clinicaltrials.gov/ct2/show/NCT01975389?termјSPIRE-2&rankј1, Published March 4, 2014 (accessed 19. 03. 14.).Clinical Trials gov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). – http://clinicaltrials.gov/ct2/show/NCT01975389?termјSPIRE-2&rankј1, Published March 4, 2014 (accessed 19. 03. 14.).Mason I. Pharma Times on line, Antibody lipid treatments enter final furlong. – https://www.pharmatimes.com/news/antibody_lipid_treatments_enter_final_furlong_1005620Mason I. Pharma Times on line, Antibody lipid treatments enter final furlong. – https://www.pharmatimes.com/news/antibody_lipid_treatments_enter_final_furlong_1005620Dadu R. T., Ballantyne C. M. Lipid lowering with PCSK9 inhibitors // Nat. Rev. Cardiol. 2014. Vol. 84. P. 1–13.Dadu R. T., Ballantyne C. M. Lipid lowering with PCSK9 inhibitors // Nat. Rev. Cardiol. 2014. Vol. 84. P. 1–13.Ecker-Schlipf B. Hyperlipidemia. New treatment option with Evolocumab // Med. Monatsschr. Pharm. 2014. Vol. 37, N 7. P. 271–272.Ecker-Schlipf B. Hyperlipidemia. New treatment option with Evolocumab // Med. Monatsschr. Pharm. 2014. Vol. 37, N 7. P. 271–272.Chan J. C., Piper D. E., Cao Q. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9820–9825.Chan J. C., Piper D. E., Cao Q. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9820–9825.Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the, proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia // Circulation. 2013. Vol. 128, N 19. P. 2113–2120.Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the, proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia // Circulation. 2013. Vol. 128, N 19. P. 2113–2120.Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial // Circulation. 2012. Vol. 126, N 20. P. 2408–2417.Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial // Circulation. 2012. Vol. 126, N 20. P. 2408–2417.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexintype 9 as monotherapy in patients with hypercholesterolaemia(MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Vol. 380, N 9858. P. 1995–2006.Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexintype 9 as monotherapy in patients with hypercholesterolaemia(MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Vol. 380, N 9858. P. 1995–2006.Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of amonoclonal antibody to proprotein convertase subtilisin/ kexin type 9 in combination with a statin in patients with hypercho lesterolaemia(LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of amonoclonal antibody to proprotein convertase subtilisin/ kexin type 9 in combination with a statin in patients with hypercho lesterolaemia(LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.Koren M. J., Giugliano R. P., Raal F. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial // Circulation. 2014. Vol. 129, N 2. P. 234–243.Koren M. J., Giugliano R. P., Raal F. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial // Circulation. 2014. Vol. 129, N 2. P. 234–243.Hirayama A., Honarpour N., Yoshida M. et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in Hypercholesterolemic, statin-treated japanesepatients at high cardiovascular risk // Circ. J. 2014. Vol. 78, N 5. P. 1073–1082.Hirayama A., Honarpour N., Yoshida M. et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in Hypercholesterolemic, statin-treated japanesepatients at high cardiovascular risk // Circ. J. 2014. Vol. 78, N 5. P. 1073–1082.Sahebkar A., watts G. F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. 2013. Vol. 35, N 8. P. 1082–1098.Sahebkar A., watts G. F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. 2013. Vol. 35, N 8. P. 1082–1098.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.Stroes E., Colquhoun D., Sullivan D. et al. Anti-PCSK9 antibodyeffectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placeboc ontrolled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2541–2548.Stroes E., Colquhoun D., Sullivan D. et al. Anti-PCSK9 antibodyeffectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placeboc ontrolled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2541–2548.Koren M. J., Lundqvist P., Bolognese M. et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2531–2540.Koren M. J., Lundqvist P., Bolognese M. et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2531–2540.Raal F. J., Honarpour N., Blom D. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 385. P. 341–350.Raal F. J., Honarpour N., Blom D. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 385. P. 341–350.Blom D. J., Hala T., Bolognese M. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia // N. Engl. J. Med. 2014. Vol. 370, N 19. P.1809–1819.Blom D. J., Hala T., Bolognese M. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia // N. Engl. J. Med. 2014. Vol. 370, N 19. P.1809–1819.Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). http://clinicaltrials.gov/show/NCT01624142 (accessedAug 9, 2014).Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). http://clinicaltrials.gov/show/NCT01624142 (accessedAug 9, 2014).Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 9, 2014).Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 9, 2014).Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV). https://clinicaltrials.gov/ct2/show/NCT01813422.Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV). https://clinicaltrials.gov/ct2/show/NCT01813422.Gusarova V., Howard V. G., Okamoto H. et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates // Clin. Lipid. 2012.Gusarova V., Howard V. G., Okamoto H. et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates // Clin. Lipid. 2012.Schaefer H., Falk E., Herling A. W. et al. Cholesterollowering effect of SAR236553/REGN727 in hamster after single s. c. injection // Drugs affecting lipid metabolism XVII international symposium e diabetes, obesity and the metabolic syndrome. Doha: Qatar. 2011. March. P. 14–16.Schaefer H., Falk E., Herling A. W. et al. Cholesterollowering effect of SAR236553/REGN727 in hamster after single s. c. injection // Drugs affecting lipid metabolism XVII international symposium e diabetes, obesity and the metabolic syndrome. Doha: Qatar. 2011. March. P. 14–16.Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.Robinson J. G., Farnier M., Krempf M. et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in 2,341 high cardiovascular risk patients: ODYSSEY LONG TERM // Latebreaking trial presentation at the American Heart Association 2014 Scientific Sessions.Robinson J. G., Farnier M., Krempf M. et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in 2,341 high cardiovascular risk patients: ODYSSEY LONG TERM // Latebreaking trial presentation at the American Heart Association 2014 Scientific Sessions.Moriarty P. M., Thompson P. D., Cannon C. P. et al. ODYSSEY ALTERNATIVE: Efficacy and safety of the proprotein convertasesubtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm // Ibid.Moriarty P. M., Thompson P. D., Cannon C. P. et al. ODYSSEY ALTERNATIVE: Efficacy and safety of the proprotein convertasesubtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm // Ibid.Bays H., Farnier M., Weiss R. et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II // Ibid.Bays H., Farnier M., Weiss R. et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II // Ibid.Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial // Am. Heart J. 2014. Vol. 168, N 5. P. 682–689.Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial // Am. Heart J. 2014. Vol. 168, N 5. P. 682–689.Ballantyne Ch. M., Neutel J., Cropp A. et. al. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia // Am. J. Cardiol. 2015. Vol. 115, N 9. P. 1212–1221.Ballantyne Ch. M., Neutel J., Cropp A. et. al. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia // Am. J. Cardiol. 2015. Vol. 115, N 9. P. 1212–1221.Marais A. D., Kim J. B., Wasserman S. M., Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels // Pharmacology & Therapeutics. 2015. Vol. 145. P. 58–66.Marais A. D., Kim J. B., Wasserman S. M., Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels // Pharmacology & Therapeutics. 2015. Vol. 145. P. 58–66.

The authors declare that there are no conflicts of interest present.